ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 651

Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus

Jing Wen1, Jessica Doerner1, Ariel Stock2, Jennifer Michaelson3, Linda Burkly3, Maria Gulinello2 and Chaim Putterman4, 1Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Biogen Idec, Cambridge, MA, 4The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cytokines, inflammation and neuropsychiatric disorders, SLE

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: While neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is relatively common and appears early, the underlying mechanisms are not fully understood. The disruption of the blood brain barrier (BBB) is believed to be one key pathological feature in NPSLE, allowing the passage of neurotoxic autoantibodies into the brain.

   TWEAK is a cytokine member of the TNF superfamily; the TWEAK receptor, Fn14, is expressed in brain endothelial cells, astrocytes, microglia and neurons. We recently found that lupus prone MRL/lpr Fn14 knockout (KO) mice display a markedly attenuated neuropsychiatric phenotype, as revealed by a significant reduction in depressive-like behavior and improved cognitive function. Morever, NPSLE patients demonstrate high levels of TWEAK in the cerebrospinal fluid (CSF). We undertook the current studies to determine the mechanisms by which TWEAK signaling is involved in the pathogenesis of NPSLE.

Methods: Brains from female MRL/lpr Fn14WT and MRL/lpr Fn14KO mice at 20 weeks of age were prepared for qRT-PCR, Western blot and immunohistochemistry (IHC). Cellular infiltrates were quantified by hematoyxlin and eosin staining. To assess BBB integrity, extravascular fibronectin and IgG deposition, VCAM/ICAM, and iNOS expression was evaluated by Western blot, IHC and qPRT-PCR, respectively. Complement activation was assessed by measuring the expression of C3, C4a and C6 by qRT-PCR and Western blot. Fluoro Jade B and TUNEL staining were employed to analyze neuronal damage and apoptosis in the brain. Furthermore, gliosis, neuron loss, and neurogenesis were assessed by immunostaining with GFAP, NeuN and Ki-67, respectively.

Results: We found that MRL/lpr Fn14KO mice had significantly improved BBB integrity, as shown by a lower CSF albumin index, decreased fibronectin and IgG deposition, and reduced brain expression of VCAM, ICAM and iNOS. Furthermore, Fn14KO mice exhibited significantly fewer cellular infiltrates in the choroid plexus compared to the Fn14WT mice. At the same time, a significant reduction in C3, C4a and C6 expression was observed in brains of Fn14KO mice. Neuronal damage, an important pathological change present in lupus animal models, was also ameliorated by Fn14 deficiency. Fn14KO mice displayed reduced apoptosis in the cortex, as well as less neuron loss and less gliosis in the hippocampus. Interestingly, there were no differences in neurogenesis and in microglia activation between Fn14KO and Fn14WT mice.

Conclusion: Our studies indicate that TWEAK/Fn14 interactions can play a central role in the pathogenesis of NPSLE by improving BBB integrity and reducing neuronal damage, suggesting this pathway as a novel target for therapeutic intervention in this disease.


Disclosure:

J. Wen,
None;

J. Doerner,
None;

A. Stock,
None;

J. Michaelson,

Biogen Idec,

2;

L. Burkly,

Biogen Idec,

2;

M. Gulinello,
None;

C. Putterman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibiting-tweak-tnf-like-weak-inducer-of-apoptosis-signaling-improves-blood-brain-barrier-integrity-and-protects-from-neuronal-damage-in-murine-neuropsychiatric-lupus-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology